Clinical features of biliary tract cancer in Japanese individuals with Lynch syndrome.

Lynch syndrome (LS) biliary tract cancer (BTC) cumulative risk microsatellite instability (MSI) mismatch repair gene (MMR gene)

Journal

Journal of gastrointestinal oncology
ISSN: 2078-6891
Titre abrégé: J Gastrointest Oncol
Pays: China
ID NLM: 101557751

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 23 02 2022
accepted: 02 08 2022
entrez: 17 11 2022
pubmed: 18 11 2022
medline: 18 11 2022
Statut: ppublish

Résumé

Biliary tract cancer (BTC) is a Lynch syndrome (LS)-associated cancer with a high mortality rate. This study aimed to clarify the clinical features of BTC in individuals with LS and to discuss its management. We obtained data from genetically verified Japanese individuals with LS who were diagnosed at a single institution, between January 2003 and April 2021. Moreover, 21 individuals with sporadic BTC (n=15) and LS associated BTC (n=6) underwent microsatellite instability (MSI) testing. Among 92 individuals with LS, 6 individuals with MSI analysis could facilitate LS identification in individuals with BTC. Surveillance for BTC should be considered for

Sections du résumé

Background UNASSIGNED
Biliary tract cancer (BTC) is a Lynch syndrome (LS)-associated cancer with a high mortality rate. This study aimed to clarify the clinical features of BTC in individuals with LS and to discuss its management.
Methods UNASSIGNED
We obtained data from genetically verified Japanese individuals with LS who were diagnosed at a single institution, between January 2003 and April 2021. Moreover, 21 individuals with sporadic BTC (n=15) and LS associated BTC (n=6) underwent microsatellite instability (MSI) testing.
Results UNASSIGNED
Among 92 individuals with LS, 6 individuals with
Conclusions UNASSIGNED
MSI analysis could facilitate LS identification in individuals with BTC. Surveillance for BTC should be considered for

Identifiants

pubmed: 36388648
doi: 10.21037/jgo-22-165
pii: jgo-13-05-2532
pmc: PMC9660066
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2532-2538

Informations de copyright

2022 Journal of Gastrointestinal Oncology. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-22-165/coif). KA had lecture fee from Merck Sharp & Dohme (MSD). The other authors have no conflicts of interest to declare.

Références

N Engl J Med. 2003 Mar 6;348(10):919-32
pubmed: 12621137
Fam Cancer. 2016 Oct;15(4):553-62
pubmed: 26837502
J Natl Cancer Inst. 2004 Feb 18;96(4):261-8
pubmed: 14970275
Clin Gastroenterol Hepatol. 2019 Nov;17(12):2416-2422
pubmed: 31306801
Clin Genet. 2008 Sep;74(3):233-42
pubmed: 18554281
J Clin Oncol. 2000 Nov 1;18(21 Suppl):81S-92S
pubmed: 11060333
Fam Cancer. 2019 Apr;18(2):211-219
pubmed: 30627969
J Hepatobiliary Pancreat Sci. 2015 Apr;22(4):249-73
pubmed: 25787274
J Clin Oncol. 2013 Mar 20;31(9):1188-95
pubmed: 23358969
Cancer Treat Rev. 2009 Jun;35(4):322-7
pubmed: 19147294
Nat Genet. 2013 Dec;45(12):1474-8
pubmed: 24185513
Lancet. 2014 Jun 21;383(9935):2168-79
pubmed: 24581682
Ann Surg. 2007 May;245(5):755-62
pubmed: 17457168
J Am Coll Surg. 2020 Apr;230(4):669-675
pubmed: 32007537
Z Gastroenterol. 2001 Nov;39(11):981-4
pubmed: 11778159
Anticancer Res. 2016 Apr;36(4):1985-9
pubmed: 27069191
Fam Cancer. 2016 Jul;15(3):385-93
pubmed: 26873718
Frontline Gastroenterol. 2020 Mar 2;12(1):62-66
pubmed: 33456743
Int J Cancer. 2002 Dec 1;102(4):407-11
pubmed: 12402311
Jpn J Clin Oncol. 2015 Feb;45(2):153-9
pubmed: 25404568
Clin Transl Oncol. 2015 Dec;17(12):982-7
pubmed: 26607930
J Gastrointest Cancer. 2018 Mar;49(1):93-96
pubmed: 29238914
J Hepatobiliary Pancreat Sci. 2022 Mar;29(3):377-384
pubmed: 34689428
Gut. 2017 Mar;66(3):464-472
pubmed: 26657901
Cancer Sci. 2021 Mar;112(3):1105-1113
pubmed: 33403729
Cancer Causes Control. 2007 May;18(4):415-22
pubmed: 17264972
Oncol Lett. 2022 Jan;23(1):4
pubmed: 34820003
Gut. 2018 Jul;67(7):1306-1316
pubmed: 28754778
Surg Clin North Am. 2019 Apr;99(2):315-335
pubmed: 30846037
Int J Cancer. 1995 Dec 20;64(6):430-3
pubmed: 8550246

Auteurs

Nobuhiko Kanaya (N)

Department of Surgery, Iwakuni Clinical Center, Yamaguchi, Japan.
Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Hideki Aoki (H)

Department of Surgery, Iwakuni Clinical Center, Yamaguchi, Japan.

Toshiaki Morito (T)

Department of Pathology, Iwakuni Clinical Center, Yamaguchi, Japan.
Department of Pathology, Kagawa Rosai Hospital, Kagawa, Japan.

Fumitaka Taniguchi (F)

Department of Surgery, Iwakuni Clinical Center, Yamaguchi, Japan.

Kunitoshi Shigeyasu (K)

Department of Surgery, Iwakuni Clinical Center, Yamaguchi, Japan.
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Chieko Tamura (C)

Medical Information & Genetic Counseling Division, FMC Tokyo Clinic, Tokyo, Japan.

Kokichi Sugano (K)

Department of Genetic Medicine, Kyoundo Hospital, Sasaki Foundation, Tokyo, Japan.

Kiwamu Akagi (K)

Division of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Saitama, Japan.

Hideyuki Ishida (H)

Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.

Kohji Tanakaya (K)

Department of Surgery, Iwakuni Clinical Center, Yamaguchi, Japan.

Classifications MeSH